These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12800091)

  • 21. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
    Gault VA; Parker JC; Harriott P; Flatt PR; O'Harte FP
    J Endocrinol; 2002 Nov; 175(2):525-33. PubMed ID: 12429050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.
    Gault VA; Irwin N; Harriott P; Flatt PR; O'Harte FP
    Cell Biol Int; 2003; 27(1):41-6. PubMed ID: 12713798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.
    O'Harte FP; Mooney MH; Flatt PR
    Diabetes; 1999 Apr; 48(4):758-65. PubMed ID: 10102692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.
    Hinke SA; Gelling RW; Pederson RA; Manhart S; Nian C; Demuth HU; McIntosh CH
    Diabetes; 2002 Mar; 51(3):652-61. PubMed ID: 11872663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
    J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
    Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
    Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.
    Tatarkiewicz K; Hargrove DM; Jodka CM; Gedulin BR; Smith PA; Hoyt JA; Lwin A; Collins L; Mamedova L; Levy OE; D'Souza L; Janssen S; Srivastava V; Ghosh SS; Parkes DG
    Diabetes Obes Metab; 2014 Jan; 16(1):75-85. PubMed ID: 23859463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
    Martin CM; Irwin N; Flatt PR; Gault VA
    Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.
    O'Harte FP; Mooney MH; Kelly CM; Flatt PR
    J Endocrinol; 2000 Jun; 165(3):639-48. PubMed ID: 10828847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.
    Venneti KC; Malthouse JP; O'Harte FP; Hewage CM
    Biochim Biophys Acta; 2011 Jul; 1814(7):882-8. PubMed ID: 21539943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.
    Hinke SA; Manhart S; Kühn-Wache K; Nian C; Demuth HU; Pederson RA; McIntosh CH
    J Biol Chem; 2004 Feb; 279(6):3998-4006. PubMed ID: 14610075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
    Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
    Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.
    Gault VA; Hunter K; Irwin N; Greer B; Green BD; Harriott P; O'Harte FP; Flatt PR
    Biol Chem; 2007 Feb; 388(2):173-9. PubMed ID: 17261080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP).
    Hinke SA; Gelling R; Manhart S; Lynn F; Pederson RA; Kühn-Wache K; Rosche F; Demuth HU; Coy D; McIntosh CH
    Biol Chem; 2003 Mar; 384(3):403-7. PubMed ID: 12715891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
    J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.